Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine

AIDS Research and Human Retroviruses

Volumn 25, Issue 3, 2009, Pages 269-275

  Campo, Rafael E ^a   Da Silva, Barbara A ^b,g   Cotte, Laurent ^c   Gathe, Joseph C ^d   Gazzard, Brian ^e   Hicks, Charles B ^f   Klein, Cheri E ^b   Chiu, Yi Lin ^b   King, Martin S ^b   Bernstein, Barry M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

^c HÔTEL DIEU   (France)

^d Therapeutic Concepts   (United States)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f DUKE UNIVERSITY   (United States)

^g Building AP30 3 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INHIBITION; BLOOD; CD4 LYMPHOCYTE COUNT; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; PLASMA; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TIME; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MEDICATION ADHERENCE; PLASMA; PYRIMIDINONES; RITONAVIR; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 65449187611     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0217     Document Type: Article

References (19)

1. Palella F, Delaney K, Moorman A, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infections. N Engl J Med 1998;338:853-860.
2. Campo RE, Lalanne R, Tanner TJ, et al.: Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2005;19:447-452.
3. Arribas JR, Pulido F, Delgado R, et al.: Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. J Acquir Immune Defic Syndr 2005;40:280-287.
4. Pierone, G Jr, Mieras, J, Bulgin-Coleman, D, et al.: A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials 2006;7:237-245.
5. Molto J, Santos JR, Negredo E, et al.: Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice. J Antimicrob Chemother 2007;60(2):436-439.
6. Schecter M and Nunes EP: Monotherapy with lopinavir/ ritonavir. Expert Opin Investig Drugs 2007;16(5):735-741.
7. Arribas J, Pulido F, Delgado R, et al.: Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance-therapy of HIV. AIDS 2008;22(2):F1-F9.
8. Cameron DW, da Silva BA, Arribas JR, et al.: 96 week results comparing lopinavir/ritonavir combination therapy induction followed by lopinavir-ritonavir monotherapy with efavirenz combination therapy. J Infect Dis 2008;198(2):234-240.
9. Delfraissy JF, Flandre P, Delaugerre C, et al.: Lopinavir/ ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral- naïve HIV-infected patients. AIDS 2008;22(3): 385-393.
10. Molina JM, Podsadecki TJ, Johnson MA, et al.: A lopinavir/ ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007;23:1505-1514.
11. King MS, Kempf D, and Brun SC: Relationship between adherence and the development of resistance in antiretroviralnaive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 2005;191:2046-2052.
12. Liu H, Golin CE, Miller LG, et al.: A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;15:968-977.
13. Melbourne KM, Geletko SM, Brown SL, et al.: Medication adherence in patients with HIV infection: A comparison of two measurement methods. AID Reader 1999;9:329-338
14. Arnsten JH, Demas PA, Farzadegan H, et al.: Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33(8):1417-1423.
15. King MS, Bernstein BM, Walmsley SL, et al.: Baseline HIV-1 RNA and CD4 cell count predict loss of virologic response to nelfinavir but not lopinavir/ritonavir in antiretroviral-naive patients. J Infect Dis 2004;190:280-284.
16. Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341(25):1865-1873.
17. Podsadecki TJ, Vrijens B, Tousset E, et al.: White coat compliance patterns make therapeutic drug monitoring a potentially unreliable tool for assessing long-term drug exposure. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006 (Abstract 590).
18. Maldarelli F, Palmer S, King MS, et al.: ART suppresses plasma HIV-1 RNA to a stable set-point predicted by pretherapy viremia. PLoS Pathog 2007;3:e46.
19. Palmer S, Maldarelli F, Wiegand A, et al.: Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Nat Acad Sci USA 2008;105:3879-3884.